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Yellow fever vaccine (YFV) has been used for over 70 years in
endemic areas. It is produced from 17D attenuated viral strain and
is rarely associated with serious adverse events (SAE), such as
anaphylaxis and YFV-associated neurotropic and viscerotropic
diseases.1
Immunosuppressed patients and patients at extremes of age are
at higher risk of developing YFV-associated adverse events (AE).1,2
The vaccine is not recommended for infants less than six months
old or for persons with altered immune status such as thymic
disorders, AIDS and immunosuppressive therapies based on a
presumed increased risk for YFV-associated SAE.3 YFV should be
deferred in persons with a history of cancer or transplant recipients
until immune recovery,4 as suggested by two reports describing
the lack of YFV AE in immune-recovered BM recipients.5,6
Mechanisms for YFV-associated neurotropic and viscerotropic
diseases are still not completely elucidated. It is likely that immune
response may not contain 17D replication, which usually follows
the ﬁrst vaccine dose.3 Indeed, a low-level viremia has been
described in primary recipients, starting 3–7 days after vaccination,
persisting for 1–3 days and decreasing as IgM Abs are produced.7
We report the case of a patient with AML who started
chemotherapy just 7 days after yellow fever (YF) vaccination.
17D viral load was monitored by RT-PCR, as well as clinical and
laboratory abnormalities. Levels of neutralizing Abs (NA) against
17D were also quantiﬁed.
The titration of NA against YF was performed at Fiocruz, Rio de
Janeiro, using a Plaque Reduction Neutralization Test8 in serial
twofold dilutions starting at 1:5, in 50 mL aliquots of heat-
inactivated (56 1C for 30min) serum, in 96-well tissue culture
plates.9 A positive in house monkey serum sample with YF Ab
content calibrated by a WHO International Reference Preparation,
with 1115mIU/mL was the reference for each set of tests,10 and
was repeated every 10 samples. After incubation at room
temperature for 1 h, a suspension of Vero cells was added and
the plates were incubated for 3 h. The medium was then discarded
and the cells overlaid with 100mL of medium containing
carboxymethylcellulose. After incubation for 7 days at 37 1C in
5% CO2, cell monolayers were ﬁxed with 10% formalin, stained
with 0.04% crystal violet and plaques counted. The mean Ab
content at the 50% end point of the standard was calculated
through linear regression. The mean titre of the standard sera
determined the levels of protection in each sample.
Total RNA was extracted from 140mL of plasma using QIAamp
RNA Blood Mini Kit (Qiagen, Hilden, Germany) and eluted in 60 mL
of elution buffer. cDNA was obtained through a reverse
transcriptase reaction using 10 mL of the extracted RNA, 300 ng
of random primer (Amersham Biosciences, Piscataway, NJ, USA);
10U/mL of Super Script TM II reverse transcriptase (Invitrogen,
Carlsbad, CA, USA) in a buffer solution with 0.25 U/mL of
ribonuclease inhibitor (Invitrogen) and 0.5mM deoxyribonucleo-
tide triphosphates (Invitrogen), at ﬁnal volume of 20 mL. The
reaction was incubated at 45 1C for 90min. Five microlitres of
cDNA was added to 20mL of TaqMan Master Mix (Applied
Biosystems, Foster City, CA, USA) and was ampliﬁed by RT-PCR
using the following primers and probe: (YF-NS5_F) 50-GCACGG
ATGTAACAGACTGAAGA-30; (YF-NS5_R) 50-CCAGGCCGAACCTGTC
AT-30 and (YF-NS5Probe) 50-FAM-CGACTGTGTGGTCCGGCCCATC-30-
TAMRA.11 The product was ampliﬁed using optical detection
system layout of BioRad ICycler for 45 cycles at the following
settings: 10min at 95 1C, followed by 45 cycles of 15 s for 94 1C and
60 s for 60 oC.
An asymptomatic 39 year-old man was diagnosed with AML
after routine blood test. BM aspiration demonstrated 76% blasts,
urging chemotherapy initiation. He had been vaccinated against
YF for the ﬁrst time 7 days before chemotherapy was started.
Detailed clinical and laboratory follow up for possible YFV-
associated AE was performed, and 17D viral load was monitored
by RT-PCR, daily for the ﬁrst 19 days after vaccination (Table 1). He
remained clinically stable, without any neurological or hepatic
abnormalities that could resemble YFV-associated neurotropic or
viscerotropic disease. 17D viral load, as measured by RT-PCR,
decreased progressively from the ﬁrst measurement, with unde-
tectable levels on day 16. NA against 17D were measured on day
28 after vaccination, and surprisingly indicated protective levels.
This is an unusual case of YF vaccination followed by
chemotherapy-induced severe immunosuppression. The 17D
viremia was documented for 15 days after vaccination, and was
not associated with detectable AE. Surprisingly, protective NA
titers were detected 1 month after the vaccine, indicating memory
B lymphocytes may have been preserved despite ablative BM
suppression.
The use of 17D in immunosuppressed patients is a common
concern in clinical practice and several points remain unknown. In
a recent review, 17D AE in vulnerable populations of children,
pregnant women, older persons, HIV positive patients and in
individuals taking immunosuppressive medications were
described. Although SAE have been identiﬁed among older
persons and breastfeeding mothers, no change in the current
understanding of the risk of 17D SAE could be provided by this
comprehensive review.12
Several inconclusive reports described mutations in 17D that
may be associated with SAE.13–16 However, a particular strain
related to the lack of AE in an immunosuppressed individual has
not been described. Host genetic susceptibilities may also have an
important role in the development of YFV AE. In previous reports,
cases of YFV AE have been associated with high and prolonged
17D viral load, abnormalities in innate immune response and
genetic polymorphisms in chemokine receptor CCR5, and its
ligand RANTES.17,18
Populations of immunosuppressed individuals are likely to
increase worldwide, raising concern about the use of live
attenuated vaccines and their possible AE. YFV zones have been
expanding in recent years in several regions of South America, in
order to prevent potential urban outbreaks of the disease.3
Understanding viral and immune response dynamics following
YFV in healthy and immunosuppressed persons is paramount to
elucidate the mechanisms for YFV-associated neurotropic and
viscerotropic diseases. Moreover, for immunosuppressed patients
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who live or travel to YF endemic zones, it is important to establish
safe vaccination guidelines, which would also grant protection
against this highly lethal but preventable disease.
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Table 1. 17D viral load and NA levels following YFV
Post-vaccine day 17DD viral load
(RNA copies/mL)
Neutralizing antibodiesa
(mUI/mL)
7b 103372 o210
8 NP 288.4
9 23822 o210
10 10664 o210
12 7508 o210
13 4343 281.1
14 4343 o210
15 2941 o210
16 o1000 465.4
17 o1000 o210
19 o1000 o210
28 NP 3102.9
Abbreviations: NP¼not performed, YFV¼ yellow fever vaccination. aNA
levels are considered positive if 794mUI/mL and higher. bPost-vaccine day
7 was the day of chemotherapy start.
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